Bourdeau, I.
51  Ergebnisse:
Personensuche X
?
3

What Is the Optimal Duration of Adjuvant Mitotane Therapy i..:

Basile, V ; Puglisi, S ; Altieri, B...
Basile , V , Puglisi , S , Altieri , B , Canu , L , Libe , R , Ceccato , F , Beuschlein , F , Quinkler , M , Calabrese , A , Perotti , P , Berchialla , P , Dischinger , U , Megerle , F , Baudin , E , Bourdeau , I , Lacroix , A , Loli , P , Berruti , A , Kastelan , D , Haak , H R , Fassnacht , M & Terzolo , M 2021 , ' What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question ' , Journal of Personalized Medicine , vol. 11 , no. 4 , 269 . https://doi.org/10.3390/jpm11040269.  , 2021
 
?
4

What is the optimal duration of adjuvant mitotane therapy i..:

Basile V ; Puglisi S ; Altieri B...
info:eu-repo/semantics/altIdentifier/pmid/33916613.  , 2021
 
?
5

ENSAT registry-based randomized clinical trials for adrenoc..:

Crona, J ; Baudin, E ; Terzolo, M...
Crona , J , Baudin , E , Terzolo , M , Chrisoulidou , A , Angelousi , A , Ronchi , CL , Oliveira , CL , van Dijkum , E , Ceccato , F , Borson-Chazot , F , Reimondo , G , Tiberi , GAM , Ettaieb , H , Kiriakopoulos , A , Letizia , C , Kastelan , D , Osher , E , Yiannakopoulou , E , Arnaldi , G , Assie , G , Paiva , I , Bourdeau , I , Newell-Price , J , Nowak , KM , Romero , MT , de Martino , MC , Bugalho , MJ , Sherlock , M , Vantyghem , MC , Dennedy , MC , Loli , P , Rodien , P , Feelders , R A , de Krijger , R , Van Slycke , S , Aylwin , S , Morelli , V , Vroonen , L , Shafigullina , Z , Bancos , I , Trofimiuk-Muldner , M , Quinkler , M , Luconi , M , Kroiss , M , Naruse , M , Igaz , P , Mihai , R , Della Casa , S , Berruti , A , Fassnacht , M & Beuschlein , F 2021 , ' ENSAT registry-based randomized clinical trials for adrenocortical carcinoma ' , European Journal of Endocrinology , vol. 184 , no. 2 , pp. R51-R59 . https://doi.org/10.1530/EJE-20-0800.  , 2021
 
?
6

What is the optimal duration of adjuvant mitotane therapy i..:

Basile V ; Puglisi S ; Altieri B...
info:eu-repo/semantics/altIdentifier/pmid/33916613.  , 2021
 
?
7

What is the optimal duration of adjuvant mitotane therapy i..:

Basile V ; Puglisi S ; Altieri B...
info:eu-repo/semantics/altIdentifier/pmid/33916613.  , 2021
 
?
8

Recovery of adrenal insufficiency is frequent after adjuvan..:

Poirier J ; Gagnon N ; Terzolo M...
info:eu-repo/semantics/altIdentifier/pmid/32164326.  , 2020
 
?
 
?
 
?
15

Antifungal susceptibility testing practices in mycology lab..:

Bellanger, A.-P ; Persat, F ; Foulet, F...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.mycmed.2020.100970.  , 2020
 
1-15